ALLO-647 + Fludarabine + Cyclophosphamide

Phase 1/2Terminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Multiple Myeloma

Conditions

Relapsed/Refractory Multiple Myeloma

Trial Timeline

Jun 6, 2021 → Oct 11, 2023

NCT ID

NCT05000450

About ALLO-647 + Fludarabine + Cyclophosphamide

ALLO-647 + Fludarabine + Cyclophosphamide is a phase 1/2 stage product being developed by Allogene Therapeutics for Relapsed/Refractory Multiple Myeloma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05000450. Target conditions include Relapsed/Refractory Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05714345	Phase 2	Terminated	Nov 1, 2023	Oct 28, 2024	Relapsed/Refractory Large B Cell Lymphoma
NCT05000450	Phase 1/2	Terminated	Jun 6, 2021	Oct 11, 2023	Relapsed/Refractory Multiple Myeloma
NCT04696731	Phase 1	Active	Feb 24, 2021	Dec 1, 2025	Advanced/Metastatic Clear Cell Renal Cell Carcinoma
NCT04416984	Phase 1/2	Active	May 21, 2020	May 1, 2029	Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
NCT03939026	Phase 1	Completed	May 1, 2019	Jan 28, 2025	Relapsed/Refractory Large B Cell Lymphoma

Competing Products

20 competing products in Relapsed/Refractory Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
agenT-797	MiNK Therapeutics	Phase 1	25
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	52
Eribulin mesylate	Eisai	Phase 2	52
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	41
ISB 1342	Glenmark Pharmaceuticals	Phase 1	33
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	77
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	41
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	52
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	33
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	33
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	41
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	33
AZD4573	AstraZeneca	Phase 2	52
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	23
Administration of AZD6738	AstraZeneca	Phase 1	33

Other Products from Allogene Therapeutics

Fludarabine + CyclophosphamidePhase 2

ALLO-647 + Fludarabine + CyclophosphamidePhase 2

ALLO-647 + Fludarabine + CyclophosphamidePhase 1/2

CyclophophamidePhase 1

ALLO-647 + Fludarabine + CyclophosphamidePhase 1